Aduro Biotech, Inc. (NASDAQ:ADRO) CEO Stephen T. Isaacs sold 16,400 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $7.96, for a total transaction of $130,544.00. Following the sale, the chief executive officer now owns 190,321 shares of the company’s stock, valued at approximately $1,514,955.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Aduro Biotech, Inc. (NASDAQ ADRO) traded up $0.10 on Thursday, hitting $8.80. 229,565 shares of the stock were exchanged, compared to its average volume of 493,675. Aduro Biotech, Inc. has a 1-year low of $6.01 and a 1-year high of $14.85.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). The company had revenue of $3.79 million during the quarter, compared to analysts’ expectations of $4.04 million. Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.54) EPS. analysts forecast that Aduro Biotech, Inc. will post -1.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/16/stephen-t-isaacs-sells-16400-shares-of-aduro-biotech-inc-adro-stock.html.

A number of equities analysts have commented on ADRO shares. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Oppenheimer Holdings, Inc. started coverage on shares of Aduro Biotech in a research report on Monday, October 30th. They set a “buy” rating and a $15.00 price objective for the company. BidaskClub upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. William Blair restated an “outperform” rating on shares of Aduro Biotech in a research report on Monday, October 2nd. Finally, Zacks Investment Research downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $19.14.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. purchased a new position in shares of Aduro Biotech in the 3rd quarter valued at about $1,023,000. Allianz Asset Management GmbH purchased a new position in shares of Aduro Biotech in the 3rd quarter valued at about $516,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Aduro Biotech by 5.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 174,478 shares of the biotechnology company’s stock valued at $1,859,000 after purchasing an additional 9,140 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Aduro Biotech by 111.5% in the 3rd quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock valued at $776,000 after purchasing an additional 38,415 shares in the last quarter. Finally, Harvard Management Co. Inc. purchased a new position in shares of Aduro Biotech in the 3rd quarter valued at about $69,418,000. Institutional investors and hedge funds own 33.63% of the company’s stock.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.